We are pleased to announce that we have expanded our preclinical model lineup by including the "Imiquimod (IMQ)-induced dermatitis model" for psoriasis.

Psoriasis is a refractory skin disease that is caused by both genetic and environmental factors.

It causes chronic inflammation characterized by the clinical appearance of erythema and scaling of the skin.

It is estimated that anywhere from 2-4% of the world’s population suffers from psoriasis, meaning that there are at least 100 million people who are affected worldwide.

Presently there are no treatments that completely cure psoriasis, with current therapy options focusing on managing symptoms of the disease.

The IMQ model is one of the most widely used models for psoriasis research, exhibiting keratinocyte hyperproliferation, immune cells infiltration, and activation of the IL-17/IL-23 axis, as seen in human psoriasis.

In addition to the IMQ model, we also have a variety of other fibrotic and inflammatory disease models in our lineup.

If you would like to learn more about our services or the IMQ model, please don't hesitate to contact us!